Thursday, September 13, 2018

US FDA News: FDA approves new kind of treatment for hairy cell leukemia

FDA approves Lumoxiti (moxetumomab pasudotox-tdfk) for the treatment of adult patients with relapsed or refractory hairy cell leukemia
Read more: FDA approves new kind of treatment for hairy cell leukemia